본문 바로가기
KERD
논문KCI 등재

Trends of the Global Hepatitis C Disease Burden: Strategies To Achieve Elimination

Brunner Nathalie|Bruggmann Philip
대한예방의학회 (The Korean Society For Preventive Medicine)|2021.07|예방의학회지 (Journal of Preventive Medicine and Public Health)|제54권 제4호|pp. 251-258|DOI 10.3961/jpmph.21.151

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

PolicyPublic healthHIVAwarenessHepatitis C
주제분류예방의학/직업환경의학

초록

Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is comparable to the one caused by human immunodeficiency virus or tuberculosis. Today, simple detection methods, highly effective and easy to administer therapies and efficient preventative measures are available to combat hepatitis C. Nevertheless, in most countries around the world, the World Health Organization target of eliminating this infectious disease and its consequences by 2030 are not being met. Significant gaps in care for hepatitis C sufferers still exist, the shortcomings ranging from education and treatment to aftercare. Hepatitis C infection was and still is not on the radar of most politicians and health authorities. National programmes and strategies to combat the disease exist or are being developed in many countries. However, for these to be implemented efficiently and successfully, clear political commitment, strong civil society actors, well-functioning public health structures and the relevant support from global donors are needed.

Abstract

Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is comparable to the one caused by human immunodeficiency virus or tuberculosis. Today, simple detection methods, highly effective and easy to administer therapies and efficient preventative measures are available to combat hepatitis C. Nevertheless, in most countries around the world, the World Health Organization target of eliminating this infectious disease and its consequences by 2030 are not being met. Significant gaps in care for hepatitis C sufferers still exist, the shortcomings ranging from education and treatment to aftercare. Hepatitis C infection was and still is not on the radar of most politicians and health authorities. National programmes and strategies to combat the disease exist or are being developed in many countries. However, for these to be implemented efficiently and successfully, clear political commitment, strong civil society actors, well-functioning public health structures and the relevant support from global donors are needed.

참고문헌 (50)

  1. Lavanchy D, "Evolving epidemiology of hepatitis C virus", Clin Microbiol Infect, 17(2), pp.107~115 (2011)
  2. Prati D, "Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage", Dig Liver Dis, 34(11), pp.812~817 (2002)
  3. Dodd RY, "Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population", Transfusion, 42(8), pp.975~979 (2002)
  4. Pozzetto B, "Health care-associated hepatitis C virus infection", World J Gastroenterol, 20(46), pp.17265~17278 (2014)
  5. Nijmeijer BM, "Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men", J Int AIDS Soc, 22(S6), pp.e25348~ (2019)
  6. Yang S, "Transmission of hepatitis B and C virus infection through body piercing: a systematic review and meta-analysis", Medicine (Baltimore), 94(47), pp.e1893~ (2015)
  7. Jafari S, "Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis", Int J Infect Dis, 14(11), pp.e928~e940 (2010)
  8. Grebely J, "Hepatitis C point-of-care diagnostics : in search of a single visit diagnosis", Expert Rev Mol Diagn, 17(12), pp.1109~1115 (2017)
  9. Falade-Nwulia O, "Oral direct-acting agent therapy for hepatitis C virus infection : a systematic review", Ann Intern Med, 166(9), pp.637~648 (2017)
  10. "Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020" (2021)[URL]
  11. "Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries" (2018)[URL]
  12. "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis" (2016)[URL]
  13. "Sixty-seventh World Health Assembly (WHA67.6): hepatitis" (2014)[URL]
  14. Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study", Lancet Gastroenterol Hepatol, 2(3), pp.161~176 (2017)
  15. "Global hepatitis report" (2017)[URL]
  16. GBD 2017 Causes of Death Collaborators, "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392(10159), pp.1736~1788 (2018)
  17. Younossi Z, "Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden", Gastroenterology, 150(7), pp.1599~1608 (2016)
  18. Lee KK, "Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study", Lancet Gastroenterol Hepatol, 4(10), pp.794~804 (2019)
  19. Cacoub P, "Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe", J Viral Hepat, 25(7), pp.811~817 (2018)
  20. Younossi ZM, "Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus", J Viral Hepat, 23(8), pp.623~630 (2016)
  21. Lindgren P, "Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals", J Viral Hepat, 28(1), pp.142~146 (2021)
  22. Pedrana A, "Global hepatitis C elimination : an investment framework", Lancet Gastroenterol Hepatol, 5(10), pp.927~939 (2020)
  23. Kind J, "In the shadow of HIV : the Cinderella hepatitis C", Suchtmed, 21(3), pp.103~110 (2019)
  24. "EASL policy statement hepatitis C elimination" (2019)[URL]
  25. "Fifth national hepatitis C strategy 2018-2022" (2018)[URL]
  26. Blindenbacher R, "The Swiss hepatitis strategy as a model for facing future health policy challenges", Health Policy, 123(7), pp.681~687 (2019)
  27. Smith S, "Global progress on the elimination of viral hepatitis as a major public health threat : an analysis of WHO Member State responses 2017", JHEP Rep, 1(2), pp.81~89 (2019)
  28. Razavi H, "Global timing of hepatitis C virus elimination in high-income countries", Liver Int, 40(3), pp.522~529 (2020)
  29. Schatz E, "The importance of civil society involvement in eliminating hepatitis C", EMJ Hepatol, 5(1), pp.48~49 (2017)
  30. Maticic M, "The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries", Harm Reduct J, 17(1), pp.89~ (2020)
  31. Scherz N, "Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment", Int J Drug Policy, 62, pp.74~77 (2018)
  32. Martin NK, "Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy", Clin Infect Dis, 57(Suppl 2), pp.S39~S45 (2013)
  33. "The negative impact of the war on drugs on public health: the hidden hepatitis C epidemic" (2013)[URL]
  34. "World drug report 2017: 29.5 million people globally suffer from drug use disorders, opioids the most harmful"[URL]
  35. Olafsson S, "Treatment as prevention for hepatitis C(TraP Hep C)-a nationwide elimination programme in Iceland using direct-acting antiviral agents", J Intern Med, 283(5), pp.500~507 (2018)
  36. "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection" (2018)[URL]
  37. Jhaveri R, "Universal screening of pregnant women for hepatitis C : the time is now", Clin Infect Dis, 67(10), pp.1493~1497 (2018)
  38. Armstrong GL, "The prevalence of hepatitis C virus infection in the United States, 1999 through 2002", Ann Intern Med, 144(10), pp.705~714 (2006)
  39. Deuffic-Burban S, "Assessing the cost-effectiveness of hepatitis C screening strategies in France", J Hepatol, 69(4), pp.785~792 (2018)
  40. "Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework" (2016)[URL]
  41. Kattakuzhy S, "Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers : a nonrandomized clinical trial", Ann Intern Med, 167(5), pp.311~318 (2017)
  42. Umutesi G, "Rwanda launches a 5-year national hepatitis C elimination plan : a landmark in sub-Saharan Africa", J Hepatol, 70(6), pp.1043~1045 (2019)
  43. Devi S, "Ukrainian health authorities adopt hepatitis C project", Lancet, 396(10246), pp.228~ (2020)
  44. "Interpellation 19.3042: federal funding for the fight against viral hepatitis" (2019)[URL]
  45. Douglass CH, "Pathways to ensure universal and affordable access to hepatitis C treatment", BMC Med, 16(1), pp.175~ (2018)
  46. Chhatwal J, "Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals", Pharmacoeconomics, 34(6), pp.551~567 (2016)
  47. Heffernan A, "Scaling up prevention and treatment towards the elimination of hepatitis C : a global mathematical model", Lancet, 393(10178), pp.1319~1329 (2019)
  48. Tordrup D, "Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30", Lancet Glob Health, 7(9), pp.e1180~e1188 (2019)
  49. Scott N, "A model of the economic benefits of global hepatitis C elimination : an investment case", Lancet Gastroenterol Hepatol, 5(10), pp.940~947 (2020)
  50. Ward JW, "What Is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats", Gastroenterology, 156(2), pp.297~310 (2019)

관련 논문AI추천

Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwo대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Elimination of hepatitis C: What would be the practical approach?Hyung Joon Yim대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제1호Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호Acute hepatitis C virus infection: clinical update and remaining challengesChen-Hua Liu, Jia-Horng Kao대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호The Incidence and Care Cascade of the Hepatitis C Virus in KoreaChon Young Eun, Jo Aejeong, Jun Dae Won, Ko Min Jung, Lee Jonghyun, Shin Ho Gyun, Yoon Eileen L.거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제6호Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling studyAaron G Lim, Andong Li, Chongqing Tan, Jing Ma, Meiyu Wu, Ouyang Xie, Sini Li, Xiaomin Wan, Xuehong Wang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호

이 간행물의 다른 논문 (8건)

Factors Affecting Public Non-compliance with Large-scale Social Restrictions to Control COVID-19 Transmission in Greater Jakarta, IndonesiaSuryaputri Indri Yunita, Arfines Prisca Petty, Rosha Bunga Christitha, Irawan Irlina Raswanti, Triwinarto Aguspp. 221-229Associations Between Compliance with Non-Pharmaceutical Interventions and Social-Distancing Policies in South Korea during the COVID-19 Pandemic황유성, 조희숙pp. 230-237Did the timing of state mandated lockdown affect the spread of COVID-19 infection? A county level ecological study in the United States of AmericaDas Anirudha, Trivedi Meghpp. 238-244Sources of Infection Among Confirmed Cases of Coronavirus Disease 2019 in the Jeju Province, KoreaHwang Moonkyong, Bae Jong-Myonpp. 245-250Network Analysis in Systems Epidemiology박주용, Choi Jaesung, 최지엽pp. 259-264
원문 보기